Major Depressive Disorder (MDD)
Conditions
Keywords
TMS, Deep Transcranial Magnetic Stimulation, MDD, Major Depressive Disorder
Brief summary
The purpose of the study is to demonstrate that the efficacy and safety of deep brain rTMS, (Transcranial Magnetic Stimulation) H7-Coil treatment as add on treatment, is as good as the FDA cleared, H1-Coil, in subjects with major depressive disorder that have been previously unsuccessfully treated with antidepressant medications.
Detailed description
This is a prospective, 6 week, double blind, randomized, controlled, multi-center trial. The study will explore the safety and efficacy of deep brain rTMS (Transcranial Magnetic Stimulation) H7-Coil treatment and demonstrate that it is as good as the FDA cleared, H1-Coil treatment as add-on for a treatment with antidepressant drugs (a bi-therapeutic treatment ) in subjects with major depressive disorder that have been previously unsuccessfully treated with antidepressant medication. Approximately 146 subjects will be enrolled in the study. The study population consists of subjects with MDD who have failed adequate medication treatment and who are in a current depressive episode. The patients will be of all racial, ethnic and gender categories, ranging from 22 to 68 years of age, and have HDRS-21≥20. Outpatients will be recruited from both academic and private research centers. The study duration is 8 weeks, with a 2 week period of screening and baseline, followed by 4 weeks of 5 daily treatments and 2 weeks of biweekly treatments. Mood and mental state will be carefully monitored through standard psychological scales and assessments during the screening and baseline and throughout treatment.
Interventions
DEVICEH7-Coil
Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
DEVICEH1-Coil
Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
Sponsors
Brainsway
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
22 Years to 68 Years
Healthy volunteers
No
Inclusion criteria
* Outpatients * Men and women 22-68 years of age * Primary DSM-IV diagnosis of Major Depression, single or recurrent episode. * Current depressive episode is less than 5 years duration * The patient did not respond to at least one but not more than four antidepressant treatments in the current episode or Patients who have not completed antidepressant trials due to intolerance to therapy of 2 or more anti-depressant medications in the current episode * Satisfactory safety screening questionnaire for transcranial magnetic stimulation * Patients not suffering from hypo or hyper-thyroidism based on pre-study TSH level or medically stabilized * Capable and willing to provide informed consent and able to adhere to the treatment schedule * Patient is stable on medication for 2 month and is not expected to change medication during all study period
Exclusion criteria
* Individuals diagnosed by the Investigator with the following conditions (current unless otherwise stated): * Depression secondary to a general medical condition, or substance-induced * History of substance abuse or dependence within the past 6 month (except nicotine and caffeine) * Any psychotic disorder (lifetime), including schizoaffective disorder, or major depression with psychotic features, Bipolar disorder, Eating disorder, Obsessive compulsive disorder * Post-traumatic stress disorder (current or within the past year) * Current generalized anxiety disorder, panic disorder or social anxiety disorder * Presence of a personality disorder (such as antisocial, schizotypal, histrionic, borderline, narcissistic) * Individuals with a significant neurological disorder or insult including, but not limited to: * Any condition likely to be associated with increased intracranial pressure * Space occupying brain lesion * Any history of seizure EXCEPT those therapeutically induced by ECT * History of cerebrovascular accident * Transient ischemic attack within two years * Cerebral aneurysm * Dementia * Mini Mental State Exam score of less than or equal to 24 * Parkinson's disease * Huntington's chorea * Multiple sclerosis * Increased risk of seizure for any reason * Individuals with hearing loss * ECT treatment within 3 months prior to the screening visit * History of treatment with Vagus Nerve Stimulation (VNS) * History of treatment with Deep Brain Stimulation (DBS) * Use of any investigational drug within 4 weeks of the randomization visit * Use of any prohibited study medication(s) * Present suicidal risk as assessed by the investigator or significant suicide risk * Any self-inflicted harm in the past 3 months not in the context of suicidal ideation * Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease * Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed * Implanted neurostimulators * History of abnormal MRI * Known or suspected pregnancy * If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the rTMS trial * Clinically significant laboratory abnormality, in the opinion of the Investigator based on CBC and biochemistry * Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse * Women: if pregnant, planning on becoming pregnant, or currently nursing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HDRS-21 Score Change From Baseline | Week 6 post randomization | Change from baseline in HDRS-21 scores at week 6 post-randomization in the H7 group compared to the H1 group |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate in HDRS-21 | Week 6 post randomization | Percentage of patients with reduction in HDRS-21 score from baseline in the H7 group compared to the H1 group |
| Remission Rate | Week 6 post randomization | Percentage of patients in remission, at week 6 post-randomization assessment |
Countries
Canada, Israel, United States
Contacts
Primary ContactAmit Ezra
Outcome results
None listed